New liposomal cocktail takes on pancreatic cancer in major trial

NCT ID NCT07238283

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 18, 2026 · Updated 26 times

Summary

This phase 3 trial compares a new chemotherapy combination (irinotecan liposome plus oxaliplatin, 5-FU, and calcium folinate) against the current standard (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who have not yet received treatment. The study aims to see if the new combo helps patients live longer. About 662 adults with good performance status and measurable tumors will participate at multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100730, China

Contact

Contact

Conditions

Explore the condition pages connected to this study.

FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER